Global CAR T Cell Therapy Clinical Pipeline Report 2022-2028: Pharma Giants are Increasingly Partnering/Collaborating with Technology Companies to Integrate Advanced Technologies – Yahoo Finance

DUBLIN, June 17, 2022 /PRNewswire/ — The “Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028
The development of CAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy.
Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support the growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments in clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.

The report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market.
The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives a competitive analysis of major market players that will give a competitive advantage to customers in their respective businesses.
Chimeric antigen receptor (CAR) T cell therapy is a novel immunotherapeutic approach that is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor).
This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.

The introduction of CAR T cell therapies has shown high adoption rates in a short span of time has propelled further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of the market.
For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy.

The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technology companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand their geographical presence.
For instance, Bayer and Atara Biotherapeutics entered into a worldwide license agreement for the development of next-generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Among drug types, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma.
Recently in 2022, regulatory bodies expanded the approval of drugs for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as the global availability of the drug is the major factors which are the major factors aiding in the dominance of these factors.

Report Highlights:
Research Methodology
Global CAR T Cell Therapy Market Opportunity > USD 15 Billion
Global & Regional Market Insight: Current & Market Forecast 2028
Approved CAR T Cell Therapies Sales Forecast Till 2028
Emerging In Vivo Induced CAR T Cell Therapies
CAR T Cell Therapy Manufacturing Cost Analysis
CAR T Cell Therapy Approval & Reimbursement Scenario By Country
Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies
Insight On More Than 600 CAR T Cell Therapies In Clinical Trials
CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase
Key Topics Covered:
1. Research Methodology

2. Chimeric Antigen Receptor (CAR) T Cell Therapy – Next Era in Immuno Oncology

3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
3.1 Structure of CAR-T Cell
3.2 1st Generation Chimeric Antigen Receptor
3.3 2nd & 3rd Generation CAR-T Cell
3.4 Principle of Chimeric Antigen Receptor Design

4. Approaches to Improve the Efficiency of CAR-T Cell Therapy

5. CAR T Cell Therapy Manufacturing Cost Analysis

6. Emerging In-Vivo Induced CAR T Cell Therapies
6.1 Need of In-Vivo CAR T Cell Therapy
6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR
6.3 Key Drug in Research & Development

7. Global CAR T Cell Therapy Market Outlook 2022 – 2028
7.1 Market Overview
7.2 Future Market Opportunity

8. Globally Approved CAR T Cell Therapies – Pricing, Dosage & Sales Analysis 2028
8.1 Tisagenlecleucel (Kymriah)
8.2 Axicabtagene Ciloleuce (Yescarta)
8.3 Brexucabtagene Autoleucel (Tecartus)
8.4 Lisocabtagene maraleucel (Breyanzi)
8.5 Idecabtagene Vicleucel (Abecma)
8.6 Relmacabtagene autoleucel (Carteyva)
8.7 Ciltacabtagene autoleucel (Carvykti)

9. US CAR T Cell Therapy Market Outlook
9.1 Approved & Key CAR T Cell Therapy Products in US
9.2 Market Overview
9.3 Current Reimbursement Scenario

10. Europe CAR T Cell Therapy Market Outlook
10.1 Approved & Key CAR T Cell Therapy Products in Europe
10.2 UK
10.3 Germany
10.4 Spain
10.5 France
10.6 Rest of Europe
10.7 Current Reimbursement Scenario

11. China CAR T Cell Therapy Market Outlook
11.1 Approved & Key CAR T Cell Therapy Products in China
11.2 Current Market Size & Forecast

12. Japan CAR T Cell Therapy Market Outlook
12.1 Approved & Key CAR T Cell Therapy Products in Japan
12.2 Market Overview
12.3 Current Reimbursement Scenario

13. South Korea CAR T Cell Therapy Market Outlook
13.1 Approved & Key CAR T Cell Therapies in South Korea
13.2 Future Market Opportunity
14. Australia CAR T Cell Therapy Market Outlook
14.1 Approved & Key CAR T Cell Products in Australia
14.2 Australia CAR T Cell Therapy Market
14.3 Current Reimbursement Scenario

15. Taiwan CAR T Cell Therapy Market Outlook

16. Global CAR T Cells Clinical Pipeline Overview
16.1 By Company
16.2 By County
16.3 By Indication
16.4 By Phase

17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.7 Phase-III
17.8 Registered

18. Marketed CAR T Cell Therapy Clinical insight
18.1 Breyanzi
18.2 CARVYKTI
18.3 Yescarta
18.4 Kymriah
18.5 Abecma
18.6 Tecartus

19. Global CAR-T Cell Therapy Market Dynamics
19.1 Favorable Parameters
19.2 Market Challenges

20. Competitive Landscape
20.1 Autolus
20.2 Bellicum
20.3 Bluebird
20.4 Celgene
20.5 Cellectis
20.6 Celyad
20.7 Eureka Therapeutics
20.8 Fortress Biotech
20.9 Immune Therapeutics
20.10 Juno Therapeutics
20.11 Kite Pharma
20.12 Novartis
20.13 Sorrento therapeutics
20.14 TILT Biotherapeutics
20.15 Ziopharm
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lwj8p4

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/global-car-t-cell-therapy-clinical-pipeline-report-2022-2028-pharma-giants-are-increasingly-partneringcollaborating-with-technology-companies-to-integrate-advanced-technologies-301570216.html
SOURCE Research and Markets
Acadia Pharmaceuticals Inc. said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer's disease, according to the Alzhei
Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months of treatment. All 35 non-ambulatory patients (Cohorts 2 and 3) and 12 of 23 ambulatory patients (Cohort 1) were receiving Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen) maintenance therapy. Related: Scholar Rock Sh
Yahoo Finance Live’s Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.
When GSK spins off its consumer health division in July, it will become one of the last drug conglomerates to shed its sideline businesses to focus on biotech-style medicines. The shift has big implications for investors—and overall public health.
Syndax Pharmaceuticals has toiled for years toward finding cancer therapies that can improve the lives of patients.
Senators pressed for ending the public health emergency and for more return to office at federal agencies during a Senate committee Thursday.
FDA advisory panel member Dr. Paul Offit says kids vaccines are a game-changer, for the roughly 20% aged 5 and under who are likely to get vaccinated.
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. It reiterates the stock with a Buy rating and a price target of $36.00. Related: Why ACADIA Pharmaceuticals Shares Are Trading Higher Today? The analysts believe the below points are left open for discussion when the AdCom members meet tomorrow: The closeness between Parkinson's disease dementia (PDD) and Alzheimer's disease dementia (ADD) in terms of disease mechanism argue
Is Pfizer stock a buy after the FDA signed off on its Covid vaccine for babies and toddlers? Is PFE stock a buy right now?
The Food and Drug Administration took the advice of a panel of advisers and authorized the COVID-19 vaccines developed by BioNTech and Pfizer and Moderna for children as young as six months old on Friday, adding the final group to the nation's vaccine program.
LONDON (Reuters) -The European Medicines Agency (EMA) started a rolling review on Friday of a variant-adapted COVID-19 vaccine from Moderna, as coronavirus cases linked to Omicron sub-variants see an uptick in the region. U.S.-based Moderna's so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID, the original strain first identified in China, and the Omicron variant. Last week, Moderna said its bivalent vaccine produced a better immune response against Omicron than the original shot.
The billionaire Microsoft co-founder, Bill Gates, has been the target of conspiracy theories that make false claims about him using COVID-19 vaccines to implant microchips in people.
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary in New Port Richey, Fla. Located at 5422 US Hwy 19, the doors will open at 9 a.m. on Thursday, June 16, 2022.
All the rich Zuckerbergs and like-minded tech bros of the world are convinced that the future is all of us living, loving, and working in a virtual reality “metaverse.” But a new study’s findings suggest that working in virtual reality will not actually increase a worker’s productivity, comfort, or wellbeing. Quite the opposite in fact.
Registered dietitians share nutritional benefits associated with watermelon and its seeds, rinds and juice. Here are the top health benefits of watermelon.
After more than two years of pandemic life, many people are familiar with the worry and fear that can be triggered by a sore throat, sniffle or fatigue: Do I have covid-19? That thought often prompts a rush to grab the nearest home coronavirus test kit or find a testing site. But sometimes when the test comes back negative, the result can have a seemingly miraculous effect. "This morning I felt tired, maybe a sore throat, was that a hint of a headache??" tweeted Vice senior staff writer Shayla L
Roche's trial aimed at preventing Alzheimer’s disease had failed. That's a bad sign for Biogen and Eli Lilly, which are pushing forward with similar drugs.
People infected with the earliest version of the Omicron variant of the coronavirus, first identified in South Africa in November, may be vulnerable to reinfection with later versions of Omicron even if they have been vaccinated and boosted, new findings suggest. Vaccinated patients with Omicron BA.1 breakthrough infections developed antibodies that could neutralize that virus plus the original SARS-CoV-2 virus, but the Omicron sublineages circulating now have mutations that allow them to evade those antibodies, researchers from China reported on Friday in Nature. Omicron BA.2.12.1, which is presently causing most infections in the United States, and Omicron BA.5 and BA.4, which now account for more than 21% of new U.S. cases, contain mutations not present in the BA.1 and BA.2 versions of Omicron.
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. Canada approves Amylyx drug Amylyx Pharmaceuticals Inc. (Nasdaq: AMLX) scored its first-ever approval from Health Canada for its amyotrophic lateral sclerosis (ALS) drug Albrioza.
Shots could be in toddlers’ arms soon, pending approval from the CDC.

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported